Related Experiment Video
Updated: Jul 4, 2026
10:04
Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Published on: October 29, 2012
Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR
Xiomara A Perez1, Tanuja Bordia, J Michael McIntosh
1The Parkinson's Institute, 675 Almanor Avenue, Sunnyvale, CA 94085, USA.
Molecular Pharmacology
|June 28, 2008
Summary
Long-term nicotine alters alpha6beta2 nicotinic acetylcholine receptor (nAChR) subtypes, impacting dopamine release. These findings suggest alpha6beta2 nAChR subtypes are key targets for smoking cessation and Parkinson's disease treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Nicotine exposure alters nicotinic acetylcholine receptor (nAChR) expression and dopaminergic function.
- The specific effects of long-term nicotine on alpha6beta2(*) nAChR, crucial for dopaminergic neurons, remain less understood.
Purpose of the Study:
- To investigate the impact of long-term nicotine treatment on the function and expression of alpha6beta2(*) nAChR in the rat striatum.
- To identify specific alpha6beta2(*) nAChR subtypes modulated by nicotine and their role in dopamine release.
Main Methods:
- Voltammetry and receptor binding studies were employed to assess dopamine release and nAChR populations.
- Experiments utilized alpha-conotoxin MII (alpha-CtxMII) and alpha4 nAChR knockout mice to selectively block and identify nAChR subtypes.
Main Results:
- Long-term nicotine treatment enhanced endogenous dopamine release in rat striatal slices.
- Nicotine decreased alpha6alpha4beta2(*) nAChR but increased alpha6(nonalpha4)beta2(*) nAChR populations.
- Dopamine release in nicotine-treated rats was primarily mediated by the alpha6(nonalpha4)beta2(*) nAChR subtype.
Conclusions:
- Long-term nicotine exposure differentially modulates alpha6beta2(*) nAChR subtypes, altering dopamine release dynamics.
- The alpha6(nonalpha4)beta2(*) nAChR subtype plays a significant role in mediating dopamine release after chronic nicotine exposure.
- Targeting specific alpha6beta2(*) nAChR subtypes may offer therapeutic potential for smoking cessation and neurological disorders like Parkinson's disease.
More Related Videos
08:47Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
10:48Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine
Published on: January 25, 2019
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:15Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...